Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammation markers and adalimumab for discogenic low back pain
2014-005722-35Phase 4Terminated
- Sponsor
- Rigshospitalet Glostrup
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in lumbodynia (LBP) and discogenic back pain, sponsored by Rigshospitalet Glostrup. Primary endpoint: Pain assessment by PainDETECT questionnaire. Started Feb 2015; status: terminated.
02
Drugs
03
Conditions
lumbodynia (LBP)discogenic back pain
Beyond the preview
Go deeper on 2014-005722-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005722-35.